Medarex

Brief Description

Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. Medarex was acquired by Bristol-Myers Squibb for $2.3 billion in July 2009.

Timeline

  • 1991: NeXstar founded. 
  • 1996: NeXstar completes its initial public offering on the Nasdaq stock exchange under the ticker symbol NXTR.
  • 1999: NeXstar licenses the immune checkpoint therapy technique for inhibiting cancer, developed by James Allison at UC Berkeley; NeXstar acquired by Gilead Sciences for $550 million; and Gilead sublicenses the rights for Allison's discovery to Medarex.
  • 2004: Based on Allison's technology, licensed from UC Berkeley, Medarex begins testing a human monoclonal antibody — named IpilimuMab — in partnership with Bristol-Myers Squibb.  
  • 2009: Medarex is acquired by Bristol Myers Squibb for $2.3 billion.
  • 2011: YervoyTM (formerly known as IpilimuMab) fast-tracked and approved by the U.S. Food and Drug Administration.
  • 2018: Inventor James Allison jointly awarded the Nobel Prize in Physiology or Medicine for the technology that became the life-saving cancer immunotherapy treatment commercialized by BMS as YervoyTM.

Inventor

James Allison

Tech Category

  • Medical Therapeutics

Join the IPIRA Mailing List

 

 
 
 
 

 

Accessibility | Nondiscrimination | Privacy